Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06450951 · ClinicalTrials.gov registry record · NA

A Personalized Biomonitoring and Report-back Intervention to Reduce Exposure to Endocrine Disrupting Chemicals

A NA study of Environmental Exposure, sponsored by Million Marker Wellness.

Active
Registry status
NA
Development phase
600
Enrollment target
1
Study location

NCT06450951: Active NA study of Environmental Exposure, sponsored by Million Marker Wellness.

NCT06450951 is a NA study of Environmental Exposure that is active but no longer recruiting, run by Million Marker Wellness. The registered enrollment target is 600 participants, above the 244-participant average among 13 other Environmental Exposure trials with a reported enrollment target (146% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06450951, a NA study of Environmental Exposure, is active but no longer recruiting, sponsored by Million Marker Wellness.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
600 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn if a personalized biomonitoring report-back and educational intervention in child-bearing aged men and women can reduce endocrine disrupting chemicals (EDCs) measured in urine, increase participants' understanding of environmental health (environmental health literacy; EHL), increase their readiness and behaviors to reduce exposures, and improve their well-being. The intervention includes EDC testing and exposure report-back, a self-directed online interactive curriculum with access to live coaches, and an online forum. The investigators hypothesize that the intervention will be more effective than EDC testing and report-back alone at reducing EDC exposures (behavior change and metabolite concentrations), as well as increasing EHL, readiness to reduce exposures, and well-being.

Primary Outcome

Urinary EDC metabolites include bisphenols, phthalates, parabens and oxybenzone

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Urinary EDC metabolite testing
  • BEHAVIORAL Educational curriculum

Study Locations (1)

Nevada

  • Renown Health - Reno

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2024-05-23
Est. Completion 2026-08-01
Phase NA
Million Marker Wellness

5 total trials

What the registry record for NCT06450951 still lists

NCT06450951 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 244-participant average among 13 other Environmental Exposure trials with a reported enrollment target (146% higher).

The record links to 1 condition, with Environmental Exposure appearing as the primary indexed condition, and to 2 interventions - of which Urinary EDC metabolite testing is the first listed.

NCT06450951 reports a single indexed study location in Nevada.

Frequently Asked Questions

What is clinical trial NCT06450951 about?

NCT06450951 is a clinical study titled "A Personalized Biomonitoring and Report-back Intervention to Reduce Exposure to Endocrine Disrupting Chemicals". The goal of this clinical trial is to learn if a personalized biomonitoring report-back and educational intervention in child-bearing aged men and women can reduce endocrine disrupting chemicals (EDCs) measured in urine, increase participants' understanding of environmental health (environmental hea...

What is the current status of trial NCT06450951?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 600 participants. The study started on 2024-05-23. Estimated completion is 2026-08-01.

What conditions does trial NCT06450951 study?

This clinical trial studies the following conditions: Environmental Exposure.

What interventions are being tested in trial NCT06450951?

The interventions under investigation include: Urinary EDC metabolite testing (DIAGNOSTIC_TEST), Educational curriculum (BEHAVIORAL).

Who is sponsoring clinical trial NCT06450951?

This trial is sponsored by Million Marker Wellness, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06450951 being conducted?

This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Environmental Exposure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06450951's enrollment target sits among peer trials

600 2nd of 13 the highest of 13 other Environmental Exposure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Environmental Exposure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06450951, the US trial registry maintained by the National Library of Medicine. NCT06450951 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.